No products in the cart.
Empagliflozin use is associated with slower progression of chronic kidney disease
1. Empagliflozin led to a lower risk of kidney disease progression in patients with chronic kidney disease (CKD) as compared ...
Tag: cardiovascular mortality
Bivalirudin during and post-percutaneous coronary intervention reduces bleeding and mortality compared to heparin monotherapy
1. Bivalirudin during percutaneous coronary intervention plus high-dose infusion after demonstrated decreased all-cause mortality compared to heparin monotherapy. 2. Risk ...
Allopurinol does not reduce cardiovascular risk for patients with ischemic heart disease without gout
1. The composite score for non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death was comparable between allopurinol (11.0%) and usual ...
Beneficial effect of intensive blood pressure control on cardiovascular and all-cause mortality not persist after trial intervention – a secondary analysis of the SPRINT trial
1. Intensive blood pressure control regime was associated with improved cardiovascular and all-cause mortality at a median follow-up point of ...
Dapagliflozin associated with reduction in cardiovascular mortality due to lower rates of death from heart failure and sudden death – Pooled analysis of DAPA-HF and DELIVER
1. In this pooled analysis of 11,007 patients with heart failure in the DAPA-HF and DELIVER trials, treatment with dapagliflozin ...
SGLT-2 inhibitors provide morbidity and mortality benefits for patients with heart failure
1. SGLT-2 inhibitors reduced time to first hospitalization and cardiovascular death among patients with preserved, mildly reduced, and reduced ejection ...
Empaglifozin reduces death in heart failure patients with preserved ejection fraction
1. Empaglifozin treatment was shown to have reduced rates of cardiovascular death or hospitalization in patients with heart failure and ...
De-escalation with clopidogrel may reduce bleeding events in patients with recent percutaneous coronary intervention
1. 12-months after randomization, the de-escalation group met the criteria for superiority (p=0.0001) with respect to the composite primary outcome ...
Long-term enzyme-inducing antiseizure medication use associated with elevated hazard of incident cardiovascular disease
1. In this cohort study, there was a dose-dependent association between enzyme-inducing antiseizure medication use and an elevated hazard of ...
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.